The Conference Platform is open.

If you have registered but have not received an email with link to the platform, please CONTACT US immediately.

Dear colleagues,

It is our honor and pleasure to invite you to the Virtual 12th International Thymic Malignancy Interest Group Annual Meeting (ITMIG 2022) to be held between September 29 and October 2, 2022.

Originally, we planned a meeting in Warsaw, but due to the safety and health of our participants and the still uncertain epidemiological situation in the world, we decided that the conference would once again be in a virtual form.

Last year, our virtual meeting was a great success with many opportunities for the Thymic Malignancy community to meet and discuss new data, challenge the standards, and build innovative projects.

We will not meet you face to face again, but we hope that our multidisciplinary program prepared under the banner of

Unity in Multiplicity

will compensate you for this inconvenience.

The CONFERENCE PROGRAM reflects the multi-specialist nature of our society, which brings together experts from various fields dealing with thymic cancers.

Some highlights of our program!

We will talk about how to avoid mistakes resulting from the lack of communication between specialists of various specialties. We will present the importance of the assessment of mediastinal lymph nodes and how to properly perform it, as well as how to deal with various, often severe complications in the treatment of mediastinal tumors. During the session on paraneoplastic symptoms, our experts will show that thymic cancers are sometimes a disease of the entire body.
Of course, there will also be a debate on a topic that still arouses a lot of emotions, i.e. what are the indications, effectiveness and methods of adjuvant treatment in thymic cancers.

In addition, we will invite you to a joint session co-organized with the Polish Lung Cancer Group (Polska Grupa Raka Płuca), where we will talk about the similarities and differences in the diagnosis and treatment options for thymic and lung cancer.

There will also be a presentation of a clinical-radiological-pathological case during the Tumor Board session.

The novelty and distinctiveness of this conference will be the PATHOLOGY WORKSHOP – a several-hour course devoted to microscopic diagnostics of neoplastic and non-neoplastic diseases of the thymus. During the course, pathologists experienced in the diagnostics of these rare diseases will present both the basics of histopathological diagnosis and the latest knowledge on the biology and pathogenesis of thymic tumors. The workshop will include both lectures and virtual microscopy sessions. We invite both thoracic pathologists and clinicians! The Workshop is endorsed by the European Society of Pathology.

There will be time for discussion, questions and answers in all sessions. Your opinions and experience are important to us and your questions are inspiring. Exchange of experiences, even if only virtual, is a key factor in the diagnosis and treatment of rare diseases.

As you may know, patients are also welcome in our conference.

See you at ITMIG2022 in autumn!

Kind regards,

Malgorzata Szolkowska, from The Institute of Tuberculosis and Lung Diseases, Warsaw, Poland (Instytut Gruźlicy i Chorób Płuc, Warszawa, Polska)
on behalf of ITMIG2022 Organizing Committee


Nicolas Girard, from Institut Curie, Institut du Thorax Curie Montsouris, Paris, France

President of ITMIG

Important dates!

Abstract submission deadline:

July 17, 2022

Notification of Abstract Acceptance:

July 31, 2022

Early Registration Deadline:

August 31, 2022

Continuing Medical Education (CME) credits

Credits for Royal College Specialists:
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University Office of CPD. You may claim a maximum of 9 hours (credits are automatically calculated).

Hours for All Health Professionals:
This is a professional learning activity which provided up to 9 hours of Continuing Education.

Malgorzata Szolkowska, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland

Edith MaromThe Chaim Sheba Medical Center, Ramat Gan, Israel

Nicolas Girard, Institut Curie, Paris, France

Andreas Rimner, Memorial Sloan Kettering Cancer Center, New York, USA

Pam Bruce, Executive Director of ITMIG, New York, USA

Our Partner

Our Vendor